bis(cyclopentenecarboxylato)- 1,2- diaminocyclohexane- platinum(II)

11/01/1986 - "PM-mediated tumor cell cytotoxicity was completely inhibited at a concentration of 10 micrograms CDDP and L-CPDP/ml but not at concentrations of 1 and 5 micrograms/ml. The differences in plasma clearance of 99mTc-labeled MLV and phagocytic capacity of the liver among animals pretreated with the maximum tolerated doses of L-CPDP (25 mg/kg), empty liposomes, or CDDP (10 mg/kg) were not statistically significant (plasma clearance % of control: 105, 110, and 100, respectively: P greater than .05; liver uptake % of control: 87, 96, and 104, respectively: P greater than .05). "
09/23/2013 - "In vivo studies of CPDP-FA NPs on a hepatoma H22 tumor-bearing mouse model reveal that they could serve as an efficient FR/NIR fluorescent probe for targeted in vivo fluorescence imaging and cancer detection in a high contrast and specific manner. "

09/23/2013 - "In vivo studies of CPDP-FA NPs on a hepatoma H22 tumor-bearing mouse model reveal that they could serve as an efficient FR/NIR fluorescent probe for targeted in vivo fluorescence imaging and cancer detection in a high contrast and specific manner. "

11/01/1986 - "L-CPDP is easy to prepare, has a high-encapsulation efficiency and stability, is not more toxic than CDDP to the monocyte-macrophage system, and is at least as effective as CDDP against L1210 leukemia."
11/01/1986 - "At the maximum tolerated doses, the antitumor activity of L-CPDP against L1210 leukemia was similar to that of CDDP when a single dose was administered [median survival of treated mice/median survival of control mice X 100 (%T/C): 181 vs. 175] and slightly higher with the use of a triple-dose schedule (%T/C: 275 vs. 225). "
12/01/1986 - "The encapsulation of CPDP in MLVs composed of DMPC:DMPG 7:3 provides an adequate vehicle for the administration of this lipophilic compound and enhances its antitumor activity against L1210 leukemia."
12/01/1986 - "The MLV-CPDP preparation with the highest antitumor activity against L1210 leukemia in vivo was DMPC:DMPG 7:3-CPDP. "
12/01/1986 - "DMPC:DMPG 7:3-CPDP is less toxic and more active against L1210 leukemia in vivo than is cisplatin. "

08/01/1970 - "1. Inhibition and excitation of spontaneous phrenic nerve discharges in response to stimulation of the sinus, glossopharyngeal, aortic and superior laryngeal (SLN) nerves has been investigated in cats.2. The inhibition, in response to a single shock, had a latency of 5-10 msec and lasted for 20-40 msec; the response to SLN stimulation was the most prolonged.3. Excitation of phrenic motoneurones also occurred and was seen either before or after the end of the inhibition of the inspiratory burst and sometimes also during expiration.4. Intravenous strychnine blocked the inhibition.5. Intracellular recording from phrenic motoneurones showed that hyperpolarization was evoked by each nerve during the central phrenic depolarizing potential (CPDP) but only rarely in the interval between these potentials.6. When the CPDP was suppressed, hyperpolarization could sometimes be evoked.7. There were no changes in amplitude or time course of hyperpolarization during the passage of current through the cell membrane. "

03/01/1985 - "Four patients with refractory or poorly responsive chronic progressive demyelinating polyneuropathy (CPDP) were treated with total lymphoid irradiation (total dose, 2000 rad) in an uncontrolled feasibility study. "